Journal Article

Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study

Karonitsch, Thomas, Mrak, Daniel, Sautner, Judith, Aletaha, Daniel, Haslacher, Helmut, Simader, Elisabeth, Radner, Helga, Tobudic, Selma, Nothnagl, Thomas, Winkler, Florian, Mandl, Peter, Perkmann, Thomas, Blüml, Stephan, Burgmann, Heinz, Winkler, Stefan

2022

Overview

ObjectiveTo assess the humoral response to messenger RNA (mRNA) vaccine of patients with systemic autoimmune rheumatic disease (SARD) and the effect of immunosuppressive medication in a matched cohort study.MethodsPatients with SARD were enrolled and matched 1:1 for sex and age with healthy control (HC) subjects. Differences in humoral response to two doses of an mRNA vaccine in terms of seroconversion rate (SCR) and SARS-CoV-2 antibody level between the two groups and the impact of treatment within patients with SARD were assessed.ResultsWe enrolled 82 patients with SARD and 82 matched HC. SCR after the first dose was lower among the patient group than that of HC (65% compared with 100% in HC, p<0.0001) but levelled up after the second dose (94% vs 100%). After the second dose, SCR was lower for patients on combination disease-modifying antirheumatic drug (DMARD) therapy compared with all other groups (81% compared with 95% for monotherapy, p=0.01; 100% for both no DMARD therapy and HC, both p<0.0001). In addition, antibody levels after both doses were lower in patients compared with HC. We found that vaccination response was determined primarily by the number of DMARDs and/or glucocorticoids received, with patients receiving combination therapy (dual and triple therapy) showing the poorest response.ConclusionsPatients with SARD showed a good response after the second vaccination with an mRNA vaccine. However, the choice of immunosuppressive medication has a marked effect on both SCR and overall antibody level, and the number of different immunomodulatory therapies determines vaccination response.

• Publisher: BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier Limited
• Subject: Antibodies / Antirheumatic Agents - therapeutic use / Cohort analysis / Cohort Studies / Connective tissue diseases / Coronaviruses / COVID-19 / COVID-19 - prevention & control / COVID-19 Vaccines / Drug dosages / Epidemiology / Glucocorticoids / Humans / Immune response (humoral) / immune system diseases / Immunomodulation / Immunosuppressive agents / Immunosuppressive Agents - therapeutic use / Infections / ISO standards / Laboratories / Lupus / mRNA / mRNA Vaccines / Pandemics / Patients / Prospective Studies / Rheumatic diseases / Rheumatic Diseases - drug therapy / Rheumatology / SARS-CoV-2 / Scleroderma / Seroconversion / Severe acute respiratory syndrome coronavirus 2 / Statistical analysis / systemic vasculitis / Vaccination / Vaccines, Synthetic